Literature DB >> 402787

C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control.

J Ludvigsson, L G Heding, Y Larsson, E Leander.   

Abstract

A group of 58 diabetics, age 6-17 years and with a duration of diabetes of 3-14 years was studied in order to show whether the nature of the clinical manifestations and the treatment at the onset of the disease are related to the subsequent C-peptide production and also whether remaining C-peptide production is related to better diabetic control. The relations between a number of clinical and laboratory variables were analysed including the degree of ketosis and the insulin dose given at onset of diabetes, the incidence of postinitial remission period, the fasting C-peptide level after the remission period, the level of insulin antibodies and the actual diabetic control expressed as the degree of glucosuria in the patients' urine tests at home. Multiple regression analysis was the main method used. Postinitial remission was positively correlated to initial insulin dose and negatively correlated to duration of ketonuria at onset. C-peptide, which was found in 24.1% of the patients was positively correlated to age at onset and initial insulin dose, but negatively correlated to ketonuria at onset. Diabetic control was positively correlated to insulin dose at onset and to C-peptide level, but negatively correlated to insulin antibodies. It could further be shown that patients who had received a more vigorous treatment immediately at onset had both a higher incidence of postinitial remission and a better diabetic control. The results suggest that an early diagnosis followed by rapid normalization of the metabolism at the onset of juvenile diabetes increase the possibility of preservation of some of the endogenous insulin production, which seems to facilitate diabetic control.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402787     DOI: 10.1111/j.1651-2227.1977.tb07830.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  39 in total

1.  Immune intervention in children with type 1 diabetes.

Authors:  Johnny Ludvigsson
Journal:  Curr Diab Rep       Date:  2010-10       Impact factor: 4.810

Review 2.  Management of diabetes mellitus.

Authors:  D I Johnston
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

3.  Modern management of the insulin dependent diabetic.

Authors:  R Tattersall
Journal:  Ir J Med Sci       Date:  1979       Impact factor: 1.568

Review 4.  Immunological aspects on IDDM in children.

Authors:  J Ludvigsson
Journal:  Indian J Pediatr       Date:  1989 Nov-Dec       Impact factor: 1.967

5.  Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset: relationship to B-cell function and partial remission.

Authors:  J Ludvigsson
Journal:  Diabetologia       Date:  1984-02       Impact factor: 10.122

6.  Overnight metabolic profiles in very young insulin-dependent diabetic children.

Authors:  C E de Beaufort; G J Bruining; P D Home; C M Houtzagers; R van Strik
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

7.  Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4 heterozygous children with type 1 (insulin-dependent) diabetes.

Authors:  M Knip; J Ilonen; A Mustonen; H K Akerblom
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

Review 8.  The insulin receptor concept and its relation to the treatment of diabetes.

Authors:  G M Ward
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

9.  HLA-types, C-peptide and insulin antibodies in juvenile diabetes.

Authors:  J Ludvigsson; J Säfwenberg; L G Heding
Journal:  Diabetologia       Date:  1977-01       Impact factor: 10.122

10.  Glycosylated hemoglobin in fractions of erythrocytes of different ages.

Authors:  C Krzisnik; J Lukac-Bajalo
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.